Clonazepam Holsten
Benzodiazepine anticonvulsant for epilepsy and seizure disorders
Quick Facts About Clonazepam Holsten
Key Takeaways About Clonazepam Holsten
- Effective anticonvulsant: Clonazepam is a potent benzodiazepine used to control various types of epileptic seizures, particularly absence seizures and myoclonic seizures
- Risk of dependence: Physical and psychological dependence can develop with regular use; treatment duration should be kept as short as clinically necessary
- Never stop abruptly: Sudden discontinuation can cause life-threatening withdrawal seizures; doses must always be tapered gradually under medical supervision
- Dangerous with opioids and alcohol: Combining clonazepam with opioids or alcohol can cause severe respiratory depression, coma, and death
- Long-acting medication: With a half-life of 30-40 hours, clonazepam provides sustained anticonvulsant coverage throughout the day
What Is Clonazepam Holsten and What Is It Used For?
Clonazepam Holsten is a benzodiazepine anticonvulsant medication containing 0.5 mg of clonazepam per tablet. It is primarily prescribed for the treatment of epilepsy, including absence seizures (petit mal), myoclonic seizures, tonic-clonic seizures, and Lennox-Gastaut syndrome. It may also be used for panic disorder and certain movement disorders.
Clonazepam belongs to the benzodiazepine class of medications, which are among the most widely prescribed drugs in neurology and psychiatry. The active substance, clonazepam, was first synthesized in 1964 and has been used clinically since 1975. It is classified under ATC code N03AE01, placing it within the antiepileptic drug category. Clonazepam Holsten is manufactured by Holsten Pharma and is available as a prescription-only medication in most countries worldwide.
The primary mechanism of action of clonazepam involves enhancing the effect of gamma-aminobutyric acid (GABA), the main inhibitory neurotransmitter in the central nervous system. Clonazepam binds to a specific site on the GABA-A receptor, increasing the frequency of chloride ion channel opening when GABA binds to the receptor. This results in greater inhibition of neuronal firing, which produces the anticonvulsant, anxiolytic, sedative, and muscle relaxant effects of the medication. Unlike some other antiepileptic drugs, clonazepam does not directly affect sodium channels or glutamate receptors.
Clonazepam is indicated for several forms of epilepsy and seizure disorders. Its primary indications include:
- Absence seizures (petit mal): Brief episodes of staring and loss of awareness, particularly common in children
- Myoclonic seizures: Sudden, brief involuntary muscle jerks that can affect the arms, legs, or entire body
- Lennox-Gastaut syndrome: A severe form of childhood epilepsy characterized by multiple seizure types and cognitive impairment
- Akinetic seizures (drop attacks): Seizures causing sudden loss of muscle tone, resulting in falls
- Panic disorder: Recurrent unexpected panic attacks with or without agoraphobia (off-label use in some regions)
- Certain movement disorders: Including some forms of myoclonus and restless legs syndrome
Clonazepam is particularly valued in epilepsy treatment because of its broad spectrum of activity against different seizure types. However, it is important to note that tolerance to the anticonvulsant effects can develop over time, which may necessitate dose adjustments or the addition of other antiepileptic medications. According to the World Health Organization (WHO), benzodiazepines including clonazepam are listed as essential medicines for the treatment of epilepsy, underscoring their importance in global health care.
Clonazepam Holsten is a controlled substance in many countries due to its potential for dependence and misuse. It should only be used under the direct supervision of a qualified healthcare provider, and the prescription should be reviewed regularly to assess the ongoing need for treatment.
What Should You Know Before Taking Clonazepam Holsten?
Before starting Clonazepam Holsten, it is essential to inform your doctor about all medical conditions, current medications, and any history of substance abuse or addiction. Clonazepam carries significant risks including dependence, respiratory depression, and severe withdrawal effects. It is contraindicated in several conditions and interacts dangerously with many other medications.
Contraindications
Clonazepam Holsten must not be taken in certain medical situations where the risks clearly outweigh any potential benefits. Your doctor will assess these contraindications before prescribing the medication. The following are absolute contraindications for clonazepam use:
- Known hypersensitivity: Allergy to clonazepam, other benzodiazepines, or any of the excipients in the tablet formulation
- Severe respiratory insufficiency: Clonazepam can further depress respiratory drive, which can be life-threatening in patients with compromised breathing
- Severe hepatic insufficiency: The liver is the primary organ responsible for metabolizing clonazepam; severe liver disease can lead to dangerous drug accumulation
- Sleep apnea syndrome: Benzodiazepines can worsen obstructive sleep apnea by relaxing upper airway muscles and depressing the respiratory center
- Myasthenia gravis: Clonazepam's muscle relaxant properties can dangerously worsen the muscle weakness characteristic of this autoimmune neuromuscular disease
- Acute narrow-angle glaucoma: Benzodiazepines may increase intraocular pressure in susceptible individuals
Warnings and Precautions
Several important warnings apply to the use of clonazepam. Patients and healthcare providers should be aware of these safety concerns throughout the course of treatment. The European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) have issued specific warnings regarding benzodiazepine use.
Physical and psychological dependence can develop within weeks of regular clonazepam use, even at therapeutic doses. The risk increases with higher doses and longer duration of treatment. Abrupt discontinuation or rapid dose reduction can cause severe withdrawal symptoms including rebound seizures, anxiety, insomnia, tremors, sweating, and in severe cases, psychosis or life-threatening status epilepticus. Doses should always be tapered gradually under medical supervision, typically reducing the dose by no more than 0.5 mg every 1-2 weeks.
Additional precautions and warnings include:
- Sedation and cognitive impairment: Clonazepam causes drowsiness, reduced alertness, and impaired concentration, which can persist into the following day. Patients should not drive or operate heavy machinery until they know how the medication affects them
- Paradoxical reactions: In rare cases, particularly in children and elderly patients, benzodiazepines can cause paradoxical reactions including agitation, irritability, aggression, hostility, and psychotic symptoms. If these occur, treatment should be discontinued
- Depression and suicidal ideation: Antiepileptic drugs, including clonazepam, have been associated with an increased risk of suicidal thoughts and behavior. Patients should be monitored for signs of depression, suicidal ideation, or unusual changes in mood
- Elderly patients: Older adults are more susceptible to the sedative and motor-impairing effects of benzodiazepines, leading to an increased risk of falls, fractures, and cognitive decline. Lower doses should be used
- Respiratory depression: Concomitant use of benzodiazepines and opioids can result in profound sedation, respiratory depression, coma, and death. This combination should be avoided when possible, and if used together, the lowest effective doses should be employed for the shortest possible duration
- Porphyria: Clonazepam should be used with caution in patients with acute porphyria
- History of substance abuse: Patients with a history of alcohol or drug abuse are at increased risk of developing dependence on benzodiazepines and should be monitored closely
Pregnancy and Breastfeeding
Clonazepam crosses the placental barrier and is excreted in breast milk, which has significant implications for use during pregnancy and breastfeeding. According to international guidelines from the WHO and EMA, the following considerations apply:
Pregnancy: Clonazepam should be avoided during pregnancy unless the clinical condition of the mother requires treatment and there are no safer alternatives. Benzodiazepine use during the first trimester has been associated with a small increased risk of congenital malformations, including cleft lip and palate, although the evidence is not conclusive. Use during the third trimester or during labor can cause neonatal effects including hypothermia, hypotonia (floppy infant syndrome), feeding difficulties, and respiratory depression. Neonates exposed to benzodiazepines during late pregnancy may develop withdrawal symptoms days to weeks after birth. Women of childbearing potential should use effective contraception while taking clonazepam.
Breastfeeding: Clonazepam is excreted in human breast milk in clinically significant amounts. Breastfed infants may experience sedation, poor feeding, and weight loss. Breastfeeding is generally not recommended during clonazepam therapy. If the mother requires continued treatment, the decision to discontinue breastfeeding or discontinue clonazepam should be made in consultation with a healthcare provider, taking into account the importance of the medication to the mother and the potential risks to the infant.
How Does Clonazepam Holsten Interact with Other Drugs?
Clonazepam interacts with numerous medications, most critically with other central nervous system (CNS) depressants including opioids, other benzodiazepines, and alcohol. These interactions can lead to enhanced sedation, respiratory depression, and potentially fatal outcomes. Understanding drug interactions is essential for safe clonazepam therapy.
Drug interactions with clonazepam are clinically significant and can affect both the safety and efficacy of treatment. Interactions occur through two main mechanisms: pharmacodynamic interactions (where two drugs have additive or synergistic effects on the body) and pharmacokinetic interactions (where one drug affects the absorption, distribution, metabolism, or elimination of another). Clonazepam is primarily metabolized by the cytochrome P450 enzyme CYP3A4 in the liver, making it susceptible to interactions with drugs that inhibit or induce this enzyme.
Major Interactions
The following drug interactions are classified as major and may require dosage adjustments, close monitoring, or avoidance of the combination entirely:
| Interacting Drug/Class | Effect | Clinical Significance |
|---|---|---|
| Opioids (morphine, oxycodone, fentanyl, codeine, tramadol) | Profound sedation, respiratory depression, coma, death | FDA Boxed Warning. Avoid combination when possible. If co-prescribed, use lowest effective doses and shortest duration |
| Alcohol (ethanol) | Severely enhanced CNS depression, respiratory depression, loss of consciousness | Absolute contraindication. Patients must avoid alcohol completely during treatment |
| Other benzodiazepines (diazepam, lorazepam, alprazolam) | Additive sedation, increased risk of respiratory depression and overdose | Avoid concurrent use. If switching between benzodiazepines, cross-taper carefully |
| Barbiturates (phenobarbital, primidone) | Enhanced CNS depression; phenobarbital also induces CYP3A4, reducing clonazepam levels | Monitor closely. Dose adjustment may be needed for both drugs |
| CYP3A4 inhibitors (ketoconazole, itraconazole, clarithromycin, ritonavir) | Increased clonazepam blood levels, prolonged sedation, increased toxicity | May require clonazepam dose reduction. Monitor for excessive sedation |
Minor Interactions
The following interactions are of lesser clinical significance but should still be communicated to your healthcare provider. They may require monitoring but typically do not necessitate dose changes:
| Interacting Drug/Class | Effect | Clinical Significance |
|---|---|---|
| Phenytoin | May alter phenytoin levels; phenytoin may reduce clonazepam levels via CYP3A4 induction | Monitor anticonvulsant drug levels when used together |
| Carbamazepine | Carbamazepine induces CYP3A4, potentially reducing clonazepam effectiveness | May need higher clonazepam doses; monitor seizure control |
| Valproic acid | May increase clonazepam levels; rare reports of absence status epilepticus when combined | Monitor for increased sedation; be aware of potential for absence status |
| Antidepressants (SSRIs, SNRIs, TCAs) | Additive sedation, particularly with tricyclic antidepressants and mirtazapine | Caution with driving and operating machinery; typically manageable with dose adjustments |
| Antihistamines (diphenhydramine, hydroxyzine) | Additive sedation and cognitive impairment | Advise patients about increased drowsiness; prefer non-sedating antihistamines |
What Is the Correct Dosage of Clonazepam Holsten?
Clonazepam Holsten dosage must be individualized based on the patient's age, medical condition, response to treatment, and tolerability. Treatment always starts at a low dose, which is gradually increased until seizure control is achieved or side effects become limiting. The typical maintenance dose for adults ranges from 2 to 8 mg daily, divided into 2-3 doses.
Proper dosing of clonazepam is critical for achieving therapeutic benefit while minimizing adverse effects. The "start low, go slow" approach is universally recommended by international guidelines, including those from the European Medicines Agency (EMA), the British National Formulary (BNF), and the International League Against Epilepsy (ILAE). Clonazepam Holsten is available as 0.5 mg tablets, which facilitates precise dose titration.
Adults
Adult Dosing (Epilepsy)
- Starting dose: 0.5 mg taken at bedtime for the first 3 days, to allow the body to adjust to the sedative effects
- Titration: Increase by 0.5 mg every 3-7 days until seizure control is achieved or side effects become intolerable
- Usual maintenance dose: 2-8 mg daily, divided into 2-3 doses. The largest portion should be taken at bedtime
- Maximum recommended dose: 20 mg daily, although doses above 8 mg rarely provide additional benefit
For panic disorder (where approved), the starting dose is typically 0.25 mg twice daily, increased to a target dose of 1 mg daily after 3 days. Some patients may require up to 4 mg daily. The dose should always be adjusted based on individual patient response and tolerability.
Children
Pediatric Dosing (Epilepsy)
- Infants and children up to 10 years (or up to 30 kg): Starting dose of 0.01-0.03 mg/kg/day divided into 2-3 doses. Increase by no more than 0.25-0.5 mg every third day
- Maintenance dose: 0.05-0.1 mg/kg/day, divided into 2-3 doses
- Maximum recommended dose: 0.2 mg/kg/day
- Children over 10 years: Follow adult dosing guidelines, starting at 0.5 mg at bedtime
Pediatric dosing requires careful weight-based calculations and close monitoring. Parents and caregivers should be educated about the signs of excessive sedation and instructed to report any unusual behavioral changes, as paradoxical reactions (agitation, hyperactivity, aggression) are more common in children than in adults.
Elderly
Elderly Patient Dosing
- Starting dose: 0.5 mg at bedtime (or 0.25 mg if the patient is frail or has hepatic impairment)
- Titration: Increase more slowly than in younger adults, with at least 7 days between dose adjustments
- Maintenance dose: Use the lowest effective dose; elderly patients typically require lower doses than younger adults
Elderly patients have altered pharmacokinetics including reduced hepatic metabolism and increased sensitivity to benzodiazepines. The risk of falls, fractures, and cognitive impairment is significantly higher in this population. The NICE guidelines and the Beers Criteria for potentially inappropriate medication use in older adults recommend avoiding long-term benzodiazepine use in the elderly whenever possible.
Missed Dose
If you miss a dose of Clonazepam Holsten, take it as soon as you remember, unless it is nearly time for your next scheduled dose. In that case, skip the missed dose and continue with your regular dosing schedule. Do not take a double dose to make up for the one you missed. If you are unsure about what to do, contact your doctor or pharmacist for advice. Missing occasional doses of an antiepileptic medication can potentially trigger breakthrough seizures, so try to take your medication at the same times each day to maintain consistent blood levels.
Overdose
An overdose of clonazepam can be life-threatening, particularly when combined with alcohol, opioids, or other CNS depressants. Symptoms of overdose include severe drowsiness, confusion, diminished reflexes, respiratory depression, loss of consciousness, and coma. If an overdose is suspected, seek emergency medical attention immediately. The benzodiazepine antagonist flumazenil may be used as an antidote under medical supervision, but its use requires caution as it can precipitate seizures in benzodiazepine-dependent patients or in those with mixed overdoses.
What Are the Side Effects of Clonazepam Holsten?
Like all medications, Clonazepam Holsten can cause side effects, although not everyone experiences them. The most common side effects include drowsiness, fatigue, dizziness, and muscle weakness. Most side effects are dose-dependent and tend to diminish as the body adjusts to the medication. Some side effects, particularly cognitive impairment and dependence, may persist with long-term use.
Side effects of clonazepam are primarily related to its action on the central nervous system. They are usually most pronounced when treatment is started or when the dose is increased, and often diminish over time as tolerance develops. However, tolerance to the sedative effects may develop at a different rate than tolerance to the anticonvulsant effects, which can complicate long-term management. The frequency classifications below are based on data from clinical trials and post-marketing surveillance reported by the EMA and FDA.
Very Common (affects more than 1 in 10 people)
- Drowsiness and sedation
- Fatigue and lethargy
- Dizziness
- Muscle weakness and hypotonia
- Impaired coordination (ataxia)
Common (affects 1 in 10 to 1 in 100 people)
- Cognitive impairment and difficulty concentrating
- Memory problems (anterograde amnesia)
- Slurred speech (dysarthria)
- Headache
- Tremor
- Decreased libido
- Dry mouth
- Nausea
- Constipation
- Blurred vision
- Weight changes
Uncommon (affects 1 in 100 to 1 in 1,000 people)
- Depression and mood changes
- Paradoxical reactions (agitation, irritability, aggression)
- Urinary incontinence or retention
- Skin rash or allergic reactions
- Increased salivation
- Changes in appetite
- Nightmares and sleep disturbances
Rare (affects fewer than 1 in 1,000 people)
- Severe allergic reactions (anaphylaxis, angioedema)
- Respiratory depression (particularly with concurrent opioid or alcohol use)
- Hepatic dysfunction (elevated liver enzymes)
- Blood dyscrasias (thrombocytopenia, leukopenia)
- Hallucinations and psychotic reactions
- Suicidal ideation
If you experience any side effects that concern you, or if you notice symptoms not listed here, contact your doctor or pharmacist immediately. Some side effects, particularly severe allergic reactions, respiratory difficulties, or suicidal thoughts, require immediate medical attention. Long-term use of clonazepam can lead to tolerance (needing higher doses for the same effect) and physical dependence (experiencing withdrawal symptoms when the drug is stopped). Cognitive effects, including impaired memory and concentration, may be more pronounced with prolonged use and are a particular concern in elderly patients.
You can help improve drug safety by reporting any side effects to your national medicines regulatory authority. In the EU, reports can be submitted through national reporting systems linked to the EMA. In the US, you can report side effects to the FDA MedWatch program. In the UK, use the Yellow Card Scheme through the MHRA.
How Should You Store Clonazepam Holsten?
Store Clonazepam Holsten at room temperature below 25°C (77°F) in the original packaging to protect from light and moisture. Keep out of the sight and reach of children and in a secure location, as clonazepam is a controlled substance with potential for misuse.
Proper storage of Clonazepam Holsten is essential to maintain the medication's potency and safety. Benzodiazepine tablets are generally stable when stored correctly, but exposure to extreme temperatures, moisture, or light can degrade the active ingredient over time. Follow these storage guidelines to ensure your medication remains effective throughout its shelf life:
- Temperature: Store at room temperature, ideally between 15°C and 25°C (59°F to 77°F). Do not store in the refrigerator or freezer. Avoid exposing the medication to temperatures above 30°C (86°F), such as in a car during summer
- Light protection: Keep the tablets in their original blister packaging or container until ready to use. Do not transfer tablets to a clear container exposed to sunlight
- Moisture: Protect from humidity. Do not store in the bathroom or near a sink. Keep the container tightly closed
- Security: As a controlled substance, clonazepam should be stored in a secure location to prevent unauthorized access, particularly by children, adolescents, and individuals with a history of substance abuse
- Shelf life: Do not use Clonazepam Holsten after the expiry date printed on the packaging. The expiry date refers to the last day of that month
- Disposal: Do not dispose of unused or expired medications in household waste or via wastewater. Return unused medication to your pharmacist for safe disposal in accordance with local regulations
If you notice any changes in the appearance of the tablets, such as discoloration, crumbling, or unusual odor, do not take them and consult your pharmacist. These changes may indicate degradation of the active ingredient.
What Does Clonazepam Holsten Contain?
Each Clonazepam Holsten tablet contains 0.5 mg of clonazepam as the active substance, along with various inactive ingredients (excipients) that serve as fillers, binders, and disintegrants to form the tablet and ensure proper drug release.
Understanding the composition of your medication is important, particularly if you have known allergies or intolerances to certain substances. The active ingredient in Clonazepam Holsten is clonazepam, a 1,4-benzodiazepine derivative with the chemical name 5-(2-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It has a molecular weight of 315.7 g/mol and appears as a light yellow crystalline powder that is practically insoluble in water.
The tablets contain the following components:
- Active substance: Clonazepam 0.5 mg per tablet
- Excipients: The inactive ingredients typically include lactose monohydrate, microcrystalline cellulose, maize starch, magnesium stearate, and other pharmaceutical-grade excipients that aid in tablet formation and dissolution
Clonazepam Holsten tablets may contain lactose monohydrate as an excipient. Patients with rare hereditary conditions of galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption should not take this medicine. If you have a known lactose intolerance, discuss this with your doctor or pharmacist before starting treatment.
The physical characteristics of the tablet (color, shape, markings) may vary depending on the specific batch and manufacturing specifications. Always verify that the tablets you receive match the description provided by your pharmacist. If you have any concerns about the appearance of your medication, contact your pharmacist before taking it.
Frequently Asked Questions About Clonazepam Holsten
Clonazepam Holsten is a benzodiazepine anticonvulsant primarily used to treat epilepsy and seizure disorders, including absence seizures (petit mal), myoclonic seizures, akinetic seizures, and Lennox-Gastaut syndrome. It may also be prescribed for panic disorder with or without agoraphobia. The medication works by enhancing the effect of the inhibitory neurotransmitter GABA in the brain, which reduces excessive electrical activity that causes seizures. It is available as 0.5 mg tablets and requires a prescription.
Yes, clonazepam carries a risk of physical and psychological dependence, particularly with prolonged use or higher doses. Dependence can develop within weeks of regular use, even at prescribed therapeutic doses. The risk is higher in individuals with a history of alcohol or substance abuse. Treatment should be kept as short as clinically necessary. When it is time to stop, the dose must be reduced gradually over weeks or months to prevent potentially dangerous withdrawal symptoms, including rebound seizures. Never stop taking clonazepam abruptly without medical supervision.
The most common side effects of Clonazepam Holsten include drowsiness, fatigue, dizziness, muscle weakness, and impaired coordination. These effects are usually most pronounced when starting treatment or after a dose increase and tend to diminish over time. Other frequently reported side effects include cognitive impairment, memory difficulties, slurred speech, headache, and dry mouth. If any side effects persist or become bothersome, consult your healthcare provider, as dose adjustments may help. Serious side effects such as respiratory depression, severe allergic reactions, or suicidal thoughts require immediate medical attention.
No, you should avoid alcohol completely while taking clonazepam. Alcohol and clonazepam are both central nervous system depressants, and their combined effects can be dangerous and unpredictable. Drinking alcohol while on clonazepam can lead to excessive sedation, severely impaired judgment and coordination, slowed breathing (respiratory depression), loss of consciousness, and in severe cases, coma or death. Even small amounts of alcohol can significantly enhance the sedative effects of clonazepam. This applies to all forms of alcohol, including beer, wine, and spirits.
Clonazepam is rapidly absorbed after oral administration, with effects typically beginning within 30 to 60 minutes. Peak blood concentrations are reached within 1 to 4 hours after taking the tablet. However, for optimal seizure control, it may take several days to weeks of consistent dosing at the appropriate therapeutic level. The medication has a long half-life of approximately 30 to 40 hours, which means it provides sustained activity and typically allows for twice-daily dosing in most patients. Your doctor will gradually increase your dose over days to weeks to find the optimal level for your condition.
Clonazepam significantly impairs the ability to drive and operate machinery, particularly when treatment is first started, when doses are increased, or when it is combined with other sedating medications or alcohol. The sedative effects may persist into the following day due to the drug's long half-life. You should not drive or operate heavy machinery until you know how clonazepam affects you personally. In many countries, driving while taking benzodiazepines is subject to legal restrictions, and you may be required to declare your medication use to your licensing authority. Discuss your driving status with your prescribing doctor.
Abruptly stopping clonazepam can be extremely dangerous. Withdrawal symptoms may include rebound seizures (which can be more severe than the original seizures), anxiety, insomnia, tremor, sweating, irritability, muscle pain, and in severe cases, psychosis or life-threatening status epilepticus (prolonged seizure activity). Withdrawal symptoms can begin within hours to days of the last dose. The dose of clonazepam should always be reduced gradually under medical supervision, typically by no more than 0.5 mg every 1 to 2 weeks. The tapering schedule should be individualized based on the dose, duration of use, and patient response.
References
This article is based on the following peer-reviewed sources and international guidelines:
- World Health Organization (WHO). WHO Model List of Essential Medicines – 23rd List (2023). Geneva: WHO; 2023. Available at: who.int
- European Medicines Agency (EMA). Summary of Product Characteristics: Clonazepam. London: EMA; 2024. Available at: ema.europa.eu
- National Institute for Health and Care Excellence (NICE). Epilepsies in children, young people and adults. NICE guideline [NG217]. London: NICE; 2024. Available at: nice.org.uk
- Joint Formulary Committee. British National Formulary (BNF). London: BMJ Group and Pharmaceutical Press; 2024. Clonazepam monograph.
- U.S. Food and Drug Administration (FDA). Klonopin (clonazepam) Prescribing Information. Silver Spring, MD: FDA; 2023.
- Brigo F, Igwe SC, Lattanzi S. Clonazepam monotherapy for treating people with newly diagnosed epilepsy. Cochrane Database of Systematic Reviews. 2022;(4):CD013028. doi:10.1002/14651858.CD013028.pub2
- International League Against Epilepsy (ILAE). Updated classification and management of epileptic seizures. Epilepsia. 2023;64(5):1159-1182.
- American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2023 Updated AGS Beers Criteria for Potentially Inappropriate Medication Use in Older Adults. J Am Geriatr Soc. 2023;71(7):2052-2081.
- Patsalos PN, et al. Antiepileptic drugs – best practice guidelines for therapeutic drug monitoring. Therapeutic Drug Monitoring. 2018;40(5):526-541.
- Edinoff AN, et al. Benzodiazepines: Uses, Dangers, and Clinical Considerations. Neurology International. 2021;13(4):594-607. doi:10.3390/neurolint13040059
About Our Medical Editorial Team
This article was written and medically reviewed by the iMedic Medical Editorial Team, comprising licensed physicians with specializations in neurology, clinical pharmacology, and epilepsy. Our team follows the GRADE evidence framework and adheres to international guidelines from the WHO, EMA, FDA, NICE, and ILAE to ensure the highest standard of medical accuracy.
Medical Writing
Content authored by specialists in neurology and clinical pharmacology with extensive experience in epilepsy management and drug safety evaluation.
Medical Review
All content independently reviewed by the iMedic Medical Review Board to verify clinical accuracy, adherence to current guidelines, and patient safety information.
Editorial standards: All drug information is based on officially approved product characteristics (SmPC/PI), peer-reviewed literature, and international treatment guidelines. Content is updated regularly to reflect the latest evidence. No commercial funding or pharmaceutical sponsorship influences our editorial content. Read our full editorial standards.